Efficacy, safety and cost-effectiveness of hydroxychloroquine in children with COVID-19: a call for evidence.



Rodríguez-Martínez, Carlos E, Fernandes, Ricardo M, Hawcutt, Daniel B ORCID: 0000-0002-8120-6507, Sinha, Ian and Pacheco, Rafael Leite
(2020) Efficacy, safety and cost-effectiveness of hydroxychloroquine in children with COVID-19: a call for evidence. Acta paediatrica (Oslo, Norway : 1992), 109 (9). pp. 1711-1712.

[img] Text
Manuscript R1 marked.doc - Author Accepted Manuscript

Download (84kB)

Abstract

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic poses a serious threat to public health and local economies around the globe. This has created an urgent need to identify effective medications for its prevention and treatment (1). Among these treatments, the off-label use of hydroxychloroquine (HCQ), a less toxic derivate of chloroquine, has become a common practice among clinicians, including pediatricians, despite lack of evidence of its clinical efficacy for this indication (especially for pediatric patients) at present time (2).

Item Type: Article
Uncontrolled Keywords: Humans, Coronavirus Infections, Hydroxychloroquine, Treatment Outcome, Evidence-Based Medicine, Child, Cost-Benefit Analysis, COVID-19 Drug Treatment
Depositing User: Symplectic Admin
Date Deposited: 03 Jun 2020 09:20
Last Modified: 08 Feb 2023 13:10
DOI: 10.1111/apa.15373
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3089398